- Home
- CDTG vs PMN Comparison
CDTG vs PMN Comparison
Compare CDTG & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- PMN
- Stock Information
- Founded
- CDTG 2012
- PMN 2004
- Country
- CDTG China
- PMN Canada
- Employees
- CDTG N/A
- PMN N/A
- Industry
- CDTG
- PMN Pharmaceuticals and Biotechnology
- Sector
- CDTG
- PMN Health Care
- Exchange
- CDTG NYSE
- PMN Nasdaq
- Market Cap
- CDTG 36.4M
- PMN 32.3M
- IPO Year
- CDTG 2024
- PMN N/A
- Fundamental
- Price
- CDTG $3.07
- PMN $0.98
- Analyst Decision
- CDTG
- PMN
- Analyst Count
- CDTG 0
- PMN 0
- Target Price
- CDTG N/A
- PMN N/A
- AVG Volume (30 Days)
- CDTG 48.0K
- PMN 89.7K
- Earning Date
- CDTG 11-26-2024
- PMN 11-26-2024
- Dividend Yield
- CDTG N/A
- PMN N/A
- EPS Growth
- CDTG 28.29
- PMN N/A
- EPS
- CDTG 0.81
- PMN N/A
- Revenue
- CDTG $34,209,919.00
- PMN N/A
- Revenue This Year
- CDTG N/A
- PMN N/A
- Revenue Next Year
- CDTG N/A
- PMN N/A
- P/E Ratio
- CDTG $3.81
- PMN N/A
- Revenue Growth
- CDTG 18.58
- PMN N/A
- 52 Week Low
- CDTG $2.12
- PMN $0.92
- 52 Week High
- CDTG $4.60
- PMN $3.10
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- PMN 42.82
- Support Level
- CDTG N/A
- PMN $0.97
- Resistance Level
- CDTG N/A
- PMN $1.08
- Average True Range (ATR)
- CDTG 0.00
- PMN 0.13
- MACD
- CDTG 0.00
- PMN -0.00
- Stochastic Oscillator
- CDTG 0.00
- PMN 1.67
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.